Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Least Burdensome' Provisions Revisited In FDA Regulatory Science Report

This article was originally published in The Gray Sheet

Executive Summary

FDA is seeking to rein in the device industry's interpretation of the "least burdensome" statutory provisions, which govern how much data regulators may ask for during pre-market reviews
Advertisement

Related Content

Senate Bill Tackles 'Least Burdensome,' Centralized IRBs, CLIA Waivers
FDA Says Some Notice-To-Industry Letters Will Be Level 1 Guidance
FDA Says Some Notice-To-Industry Letters Will Be Level 1 Guidance
To Speed Guidance Development, CDRH Will Need More Resources – Shuren
To Speed Guidance Development, CDRH Will Need More Resources – Shuren
FDA To Expand Program For Flagging Device Safety "Signals"
Shuren's CDRH Sets Ambitious 2010 Agenda: 510(k), PMA Changes Planned
Shuren's CDRH Sets Ambitious 2010 Agenda: 510(k), PMA Changes Planned

Topics

Advertisement
UsernamePublicRestriction

Register

MT029232

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel